Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial

Hepatology Research

Volumn 44, Issue 9, 2014, Pages 956-963

  Alvares da Silva, Mario Reis ^a,b   de Araujo, Alexandre ^b   Vicenzi, João Reinhardt ^a   da Silva, Gabriel Veber ^a   Oliveira, Fabiana Bazanella ^a   Schacher, Fernando ^a   Oliboni, Lucas ^a   Magnus, Aline ^a   Kruel, Leticia Pinto ^b   Prieb, Rita ^b   Fernandes, Luiz Nelson Teixeira ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cirrhosis; Flicker test; L ornithine l aspartate; Minimal hepatic encephalopathy; Psychometric test

Indexed keywords

ORNITHINE ASPARTATE; PLACEBO;

ADULT; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CHILD PUGH SCORE; CONTROLLED STUDY; CRITICAL FLICKER FUSION TEST; DIGIT SYMBOL SUBSTITUTION TEST; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MINI MENTAL STATE EXAMINATION; NUMBER CONNECTION TEST; PATIENT COMPLIANCE; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISUAL ACUITY CHART;

EID: 84907856389     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12235     Document Type: Article

References (28)

1. Duarte-Rojo A, Estradas J, Hernández-Ramos R, Ponce-de-León S, Córdoba J, Torre A. Validation of the psychometric hepatic encephalopathy score (PHES) for identifying patients with minimal hepatic encephalopathy. Dig Dis Sci 2011; 56: 3014-3023.
2. Bajaj JS, Cordoba J, Mullen KD etal. Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011; 33: 739-747.
3. Romero-Gómez M. Pharmacotherapy of hepatic encephalopathy in cirrhosis. Expert Opin Pharmacother 2010; 11: 1317-1327.
4. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45: 549-559.
5. Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2011; 23: 1250-1257.
6. Bajaj JS, Saeian K, Christensen KM etal. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707-1715.
7. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011; 11: CD008716.
8. Bajaj JS, Heuman DM, Wade JB etal. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478-487.
9. Schmid M, Peck-Radosavjevic M, König F, Mittermaier C, Gangl A, Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int 2010; 30: 574-582.
10. Weissenborn K, Rückert N, Hecker H, Manns MP. The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy. J Hepatol 1998; 28: 646-653.
11. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980; 10: 189-209.
12. Mullen KD, Prakash RK. Management of covert hepatic encephalopathy. Clin Liver Dis 2012; 16: 91-93.
13. Butterworth RF. Editorial: rifaximin and minimal hepatic encephalopathy. Am J Gastroenterol 2011; 106: 317-318.
14. Dhiman RK, Chawla YK. Minimal hepatic encepahlopathy. Indian J Gastroenterol 2009; 28: 5-16.
15. Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. Metab Brain Dis 2011; 26: 135-139.
16. Dhiman RK, Kurmi R, Thumburu KK etal. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci 2010; 55: 2381-2390.
17. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2011; 23: 725-732.
18. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537-547.
19. Kircheis G, Knoche A, Hilger N etal. Hepatic encephalopathy and fitness to drive. Gastroenterology 2009; 137: 1706-1715.
20. Bajaj JS, Saeian K, Hafeezullah M, Hoffmann RG, Hammeke TA. Patients with minimal hepatic encephalopathy have poor insight into their driving skills. Clin Gastroenterol Hepatol 2008; 6: 1135-1139.
21. Bajaj JS, Saeian K, Schubert CM etal. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50: 1175-1183.
22. Cohen SM, Kim A, Metropulos M, Ahn J. Legal ramifications for physicians of patients who drive with hepatic encephalopathy. Clin Gastroenterol Hepatol 2011; 9: 156-160.
23. Bittencourt PL, Strauss E, Terra C, Alvares-da-Silva MR. Hepatic encephalopathy: report of the 1st monothematic meeting of the Brazilian Society. GED Gastroenterol Endosc Dig 2011; 30 (S): 10-34.
24. Bass NM, Mullen KD, Sanyal A etal. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081.
25. Bai M, Yang Z, Qi X, Fan D, Han G. L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013; 28: 783-792.
26. Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2012; 27: 1329-1335.
27. Najmi AK, Pillai KK, Pal SN, Akhtar M, Aqil M, Sharma M. Effect of l-ornithine l-aspartate against thiocetamide-induced hepatic damage in rats. Indian J Pharmacol 2010; 42: 384-387.
28. McPhail MJ, Leech R, Grover VP etal. Modulation of neural activation following treatment of hepatic encephalopathy. Neurology 2013; 80: 1041-1047.